SCHEMBL419275

SCHEMBL419275

O=C(COc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)Nc1ccc(-c2ccoc2)cc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 16/20 0.66
EPAS1 Q99814 8/20 0.66
SERPINE1 P05121 2/20 0.56
MDH2 P40926 2/20 0.51
MDH1 P40925 1/20 0.51
EP300 Q09472 1/20 0.51
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
CASP2 P42575 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416802 0.91 HIF1A (0.59) HIF1AEPAS1SERPINE1MDH2MDH1
SCHEMBL417064 0.83 SERPINE1 (0.71) SERPINE1MEN1RAB9AKMT2A
SCHEMBL416752 0.82 HIF1A (0.74) HIF1AEPAS1SERPINE1MDH2MDH1
SCHEMBL4293719 0.80 HIF1A (1.00) HIF1AEPAS1MDH2MDH1EP300
SCHEMBL4297107 0.79 HIF1A (0.67) HIF1AEPAS1SERPINE1MDH2MDH1
SCHEMBL418061 0.78 SERPINE1 (0.80) SERPINE1MEN1RAB9AKMT2A
SCHEMBL417355 0.77 SERPINE1 (0.81) SERPINE1MEN1RAB9AKMT2A
SCHEMBL416810 0.74 SERPINE1 (0.60) SERPINE1RAB9AKMT2A
SCHEMBL419088 0.74 SERPINE1 (0.76) SERPINE1MEN1RAB9AKMT2A
SCHEMBL4297100 0.74 HIF1A (0.79) HIF1AEPAS1MDH2MDH1EP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4039276-A1 INHIBITOR AGAINST EXPRESSION OF IMMUNE CHECKPOINT MOLECULE Renascience Inc. (JP) 2022-08-10 EP disclosed
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 HIF1A 190/4885EPAS1 133/4885SERPINE1 1/4885
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 HIF1A 561/4885EPAS1 256/4885SERPINE1 1/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 HIF1A 561/4885EPAS1 256/4885SERPINE1 1/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 HIF1A 183/4885EPAS1 153/4885SERPINE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.